ESPERION THERAPEUTICS INC (ESPR)
Health Care · NASDAQ
Esperion commercializes NEXLETOL and NEXLIZET, first-in-class non-statin ACLY inhibitors proven to reduce cardiovascular risk in statin-intolerant or statin-unwilling patients with elevated cholesterol.
What ESPERION THERAPEUTICS INC does
Esperion is a commercial-stage biopharmaceutical company that has developed and is commercializing FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL cholesterol and cardiovascular disease risk. The company's lead products are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are first-in-class ACLY (ATP Citrate Lyase) inhibitors approved in the U.S., Europe, and other territories. Beyond its approved bempedoic acid franchise, Esperion is advancing a preclinical pipeline of next-generation ACLY inhibitors and pursuing business development to expand its commercial portfolio.
Themes: ["cardiovascular disease / LDL cholesterol management","non-statin therapies","ACLY inhibitors","hyperlipidemia / hypercholesterolemia treatment"]
Fundamentals
- Price$3.19 as of 2026-07-09 close
- Market cap$822M as of 2026-07-10
- 1-year return+159.3% as of 2026-07-09 close
- Net margin-1.8% as of 2026-07-10
- Gross margin+68.4% as of 2026-07-10
- ROE-59.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+61.1% as of 2026-07-10
- Revenue CAGR (3y)+74.8% SEC XBRL
- Beta1.15 as of 2026-07-10
Key risks (from latest filing)
["Commercial execution risk: reliance on successful market penetration of NEXLETOL and NEXLIZET in the U.S. and Europe to drive revenue growth and achieve profitability","Significant debt and royalty obligations: company carries convertible notes, long-term debt, and royalty sale liabilities totaling approximately $441 million, creating ongoing interest expense burden despite recent profitability approach","Competitive and regulatory risk: non-statin cholesterol management faces competition from established therapies (PCSK9 inhibitors, inclisiran) and GLP-1 agonist obesity drugs which may reduce cardiovascular event risk in high-risk patients"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.